Viewing Study NCT06863233


Ignite Creation Date: 2025-12-25 @ 2:54 AM
Ignite Modification Date: 2025-12-31 @ 10:55 AM
Study NCT ID: NCT06863233
Status: RECRUITING
Last Update Posted: 2025-08-12
First Post: 2025-03-03
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
Organization:

Study Overview

Official Title: Assessment of Patients Immune Response After Treatment With Engineered Tumor Infiltrating Lymphocyte Therapy Incorporating CD8 PET Imaging
Status: RECRUITING
Status Verified Date: 2025-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: